FDA approves Hemlibra-To Prevent Bleeding In Hemophilia A

The U.S. Food and Drug Administration on November 16, 2017  approved Hemlibra (emicizumab-kxwh) to stop or scale back the frequency of bleeding episodes in adult and paediatric patients with hemophilia A who have developed antibodies known as factor viii (FVIII) inhibitors.The Fda Granted approval to Genentech, Inc.

  • Hemophilia A is an hereditary blood disorder that primarily affects males. consistent with the National Institutes of Health, haemophilia affects one in every 5,000 males born within the united states, more or less 80 p.c of whom have hemophilia A. Patients with hemophilia A are missing a gene that produces factor viii, a supermolecule that permits blood to clot. Patients might experience recurrent episodes of significant harm, primarily into their joints, which may be severely damaged as a result. Some patients develop an immune reaction called a FVIII inhibitor or antibody. The antibody interferes with the effectiveness of presently offered treatments for haemophilia.
  • “Reducing the frequency or preventing bleeding episodes is a crucial part of disease management for patients with hemophilia. Today’s approval provides a brand new preventative treatment that has been shown to considerably reduce the amount of bleeding episodes in patients with hemophilia A with factor viii inhibitors,” said Richard Pazdur, M.D., acting director of the office of medicine and oncology products in the FDA’s Center for Drug evaluation and research and director of the FDA’s oncology Center of Excellence. “In addition, patients treated with Hemlibra reported an improvement in their physical functioning.”
  • Hemlibra may be a first-in-class therapy that works by bridging other Factors in the blood to restore blood coagulation for these patients. Hemlibra may be a preventative (prophylactic) treatment given weekly via injection below the skin (subcutaneous).
  • The safety and efficaciousness of Hemlibra was based on information from 2 clinical trials. the primary was an effort that included 109 males aged 12 and older with hemophilia A with FVIII inhibitors. The randomised portion of the trial compared Hemlibra to no prophylactic treatment in 53 patients who were previously treated with on-demand therapy with a bypassing agent before enrolling within the trial. Patients taking Hemlibra experienced approximately 2.9 treated bleeding episodes annually compared to about 23.3 treated harm episodes annually for patients who failed to receive prophylactic treatment. This represents an 87 p.c reduction in the rate of treated bleeds. The trial additionally included patient-reported Quality of Life metrics on physical health. Patients treated with Hemlibra reported an improvement in hemophilia-related symptoms (painful swellings and joint pain) and physical functioning (pain with movement and problem walking) compared to patients who didn’t receive prophylactic treatment.Common side effects of Hemlibra include injection site reactions, joint pain (arthralgia)and headache.
  • The second trial was a single arm trial of 23 males below the age of 12 with haemophilia A with FVIII inhibitors. throughout the trial, 87 p.c of the patients taking Hemlibra didn’t experience a bleeding episode that needed treatment.
  • The labeling for Hemlibra contains a boxed warning to alert healthcare professionals and patients that severe blood clots (thrombotic microangiopathy and thromboembolism) are discovered in patients who were additionally given a rescue treatment (activated prothrombin complex concentrate) to treat bleeds for twenty-four hours or more while taking Hemlibra.
  • The Food and Drug Administration granted this application Priority Review and Breakthrough therapy designations. Hemlibra additionally received Orphan Drug designation, that provides incentives to help and encourage the development of medication for rare diseases.

Related article: FDa approves Mavyret for Hepatits C 

Leave a Comment